NCT03023202
招募中
不适用
UWCCC Precision Medicine Molecular Tumor Board Registry
概览
- 阶段
- 不适用
- 干预措施
- PMMTB (Precision Medicine Molecular Tumor Board)
- 疾病 / 适应症
- Hematologic Neoplasms
- 发起方
- University of Wisconsin, Madison
- 入组人数
- 10000
- 试验地点
- 1
- 主要终点
- Benefit from PMMTB recommended treatment
- 状态
- 招募中
- 最后更新
- 19天前
概览
简要总结
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
研究者
入排标准
入选标准
- •Clinically suspected or histologically confirmed solid or hematological malignancy
- •Undergoing genetic testing of tumor
- •Ability to understand written informed consent document
- •Willingness to sign written informed consent document
排除标准
- •Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
研究组 & 干预措施
PMMTB
This study of the PMMTB will include all patients \>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures.
干预措施: PMMTB (Precision Medicine Molecular Tumor Board)
结局指标
主要结局
Benefit from PMMTB recommended treatment
时间窗: Up to 5 years
Whether patients benefit from PMMTB recommended treatment
Frequency of acceptance of molecular tumor board recommendations
时间窗: Up to 5 years
How often the molecular tumor board's recommendations are accepted
次要结局
- Correlation of mutations with protein overexpression(Up to 5 years)
- Correlations of mutations with spheroid culture investigations(Up to 5 years)
- Correlations of mutations with circulating tumor DNA(Up to 5 years)
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual CareNon-Small Cell Lung CancerNCT05254795Timothy Mullett659
招募中
不适用
Molecular Tumor Board at the Center for Personalized Medicine TübingenAdvanced CancerNCT03503149University Hospital Tuebingen1,000
招募中
不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/ADRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000
招募中
2 期
CAncer TReatment INformed by the Molecular Tumor Board At DartmouthCancerNCT05405413Dartmouth-Hitchcock Medical Center192
进行中（未招募）
1 期
Tumor profilingPatients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-005341-44-ATMedical University of Graz64